OncoSil Medical Ltd. said the U.S. Food and Drug Administration granted breakthrough device designation to OncoSil device for treating pancreatic cancer in combination with chemotherapy.

The tag will allow for expedited approval of the device, as it may provide more effective treatment of life-threatening or irreversibly debilitating diseases.

OncoSil device is implanted into the patient's pancreatic tumor to deliver a specific dose of the drug.

New South Wales, Australia-based OncoSil Medical develops localized treatments for pancreatic and liver cancer.